Hypothesis: Cimzia provides superior reduction in endoscopic and clinical recurrence rates
compared to mesalamine in the treatment of Crohn's disease one-year following ileocolectomy
for Crohn's disease.
1. To evaluate the difference in clinical recurrence rates between certolizumab and
mesalamine after 4 weeks, 3 months, 6 months, 9 months, and 12 months of use following
ileocolectomy for Crohn's disease using the Crohn's Disease Activity Index (CDAI).
2. To compare the endoscopic recurrence rates at one year following surgery between
patients treated with certolizumab and mesalamine.
3. To compare medication side-effects and tolerance of therapy, including the need to
interrupt therapy due to side-effects, the incidence of opportunistic infections, and a
general assessment of each patient's health and well-being using the short-form 36
(SF-36).